← Back to All US Stocks

IDXX Stock Analysis 2026 - IDEXX LABORATORIES INC /DE AI Rating

IDXX Nasdaq In Vitro & In Vivo Diagnostic Substances DE CIK: 0000874716
Recently Updated • Analysis: Apr 11, 2026 • SEC Data: 2025-12-31
STRONG BUY
88% Conf
Pending
Analysis scheduled

📊 IDXX Key Takeaways

Revenue: $4.3B
Net Margin: 24.6%
Free Cash Flow: $1.1B
Current Ratio: 1.23x
Debt/Equity: 0.28x
EPS: $13.08
AI Rating: STRONG BUY with 88% confidence

Is IDXX a Good Investment? Thesis Analysis

Claude

IDEXX demonstrates exceptional operational excellence with 31.6% operating margins, 66% ROE, and accelerating earnings growth (EPS +22.6% vs revenue +10.4%), indicating strong operating leverage in its diagnostics business. The company maintains a conservative 0.28x debt/equity ratio while generating robust $1.1B free cash flow, providing substantial financial flexibility for growth and shareholder returns.

Why Buy IDXX? Key Strengths

Claude
  • + Exceptional profitability: 61.8% gross margin and 31.6% operating margin demonstrate strong pricing power and operational efficiency
  • + Outstanding capital returns: 66% ROE and 31.6% ROA significantly exceed peer averages, indicating exceptional asset deployment
  • + Accelerating earnings growth: EPS growing 22.6% YoY vs revenue growth of 10.4% signals strong operational leverage and margin expansion
  • + Conservative financial structure: 0.28x debt/equity ratio with 171.9x interest coverage provides substantial financial flexibility
  • + Strong cash generation: $1.1B free cash flow with 24.6% FCF margin demonstrates resilient business model and effective capital conversion

IDXX Investment Risks to Consider

Claude
  • ! Liquidity compression: Current ratio of 1.23x and quick ratio of 0.90x suggest near-term working capital constraints; requires monitoring
  • ! Elevated insider activity: 18 Form 4 filings in 90 days warrants investigation into transaction nature and motivations
  • ! Execution risk: Sustaining 31.6% operating margins amid inflationary pressures and competitive dynamics in diagnostics market

Key Metrics to Watch

Claude
  • * Gross margin trend - sustainability amid cost inflation and competitive pressures
  • * Organic revenue growth rate - distinguishing organic expansion from acquisition contributions
  • * Free cash flow conversion - maintenance of 24.6% FCF margin relative to net income
  • * Current and quick ratio trends - liquidity position monitoring
  • * Debt levels and leverage ratios - capital structure evolution

IDXX Financial Metrics

Revenue
$4.3B
Net Income
$1.1B
EPS (Diluted)
$13.08
Free Cash Flow
$1.1B
Total Assets
$3.4B
Cash Position
$180.1M

💡 AI Analyst Insight

The 24.6% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments.

IDXX Profitability Ratios

Gross Margin 61.8%
Operating Margin 31.6%
Net Margin 24.6%
ROE 66.0%
ROA 31.6%
FCF Margin 24.6%

IDXX vs Default Sector

How IDEXX LABORATORIES INC /DE compares to Default sector averages

Net Margin
IDXX 24.6%
vs
Sector Avg 12.0%
IDXX Sector
ROE
IDXX 66.0%
vs
Sector Avg 15.0%
IDXX Sector
Current Ratio
IDXX 1.2x
vs
Sector Avg 1.8x
IDXX Sector
Debt/Equity
IDXX 0.3x
vs
Sector Avg 0.7x
IDXX Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is IDXX Overvalued or Undervalued?

Based on fundamental analysis, IDEXX LABORATORIES INC /DE appears fundamentally strong relative to the Default sector in 2026.

Return on Equity
66.0%
Sector avg: 15%
Net Profit Margin
24.6%
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
0.28x
Sector avg: 0.7x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

IDXX Balance Sheet & Liquidity

Current Ratio
1.23x
Quick Ratio
0.90x
Debt/Equity
0.28x
Debt/Assets
52.1%
Interest Coverage
171.92x
Long-term Debt
$450.0M

IDXX 5-Year Financial Trend & Growth Analysis

IDXX 5-year financial data: Year 2021: Revenue $3.2B, Net Income $427.7M, EPS $4.89. Year 2022: Revenue $3.4B, Net Income $581.8M, EPS $6.71. Year 2023: Revenue $3.7B, Net Income $744.8M, EPS $8.60. Year 2024: Revenue $3.9B, Net Income $679.1M, EPS $8.03. Year 2025: Revenue $4.3B, Net Income $845.0M, EPS $10.06.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: IDEXX LABORATORIES INC /DE's revenue has grown significantly by 34% over the 5-year period, indicating strong business expansion. The most recent EPS of $10.06 reflects profitable operations.

IDXX Growth Metrics (YoY)

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
24.6%
Free cash flow / Revenue

IDXX Quarterly Performance

Quarterly financial performance data for IDEXX LABORATORIES INC /DE including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q3 2025 $975.5M $203.3M $2.80
Q2 2025 $1.0B $203.3M $2.44
Q1 2025 $964.1M $235.6M $2.81
Q3 2024 $915.5M $203.3M $2.53
Q2 2024 $943.6M $203.3M $2.44
Q1 2024 $900.2M $214.1M $2.55
Q3 2023 $841.7M $132.0M $2.15
Q2 2023 $860.5M $132.0M $1.56

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

IDXX Capital Allocation

Operating Cash Flow
$1.2B
Cash generated from operations
Stock Buybacks
$1.2B
Shares repurchased (TTM)
Capital Expenditures
$124.7M
Investment in assets
Dividends
None
No dividend program

IDXX SEC 10-K & 10-Q Filing Analysis

Access official SEC EDGAR filings for IDEXX LABORATORIES INC /DE (CIK: 0000874716)

📋 Recent SEC Filings

Date Form Document Action
Mar 27, 2026 DEF 14A idxx-20260327.htm View →
Mar 26, 2026 8-K tm269826d1_8k.htm View →
Mar 5, 2026 4 xslF345X05/wk-form4_1772748092.xml View →
Mar 5, 2026 4 xslF345X05/wk-form4_1772748086.xml View →
Mar 2, 2026 4 xslF345X05/wk-form4_1772488807.xml View →

Frequently Asked Questions about IDXX

What is the AI rating for IDXX?

IDEXX LABORATORIES INC /DE (IDXX) has an AI rating of STRONG BUY with 88% confidence, based on fundamental analysis of SEC EDGAR filings.

What are IDXX's key strengths?

Claude: Exceptional profitability: 61.8% gross margin and 31.6% operating margin demonstrate strong pricing power and operational efficiency. Outstanding capital returns: 66% ROE and 31.6% ROA significantly exceed peer averages, indicating exceptional asset deployment.

What are the risks of investing in IDXX?

Claude: Liquidity compression: Current ratio of 1.23x and quick ratio of 0.90x suggest near-term working capital constraints; requires monitoring. Elevated insider activity: 18 Form 4 filings in 90 days warrants investigation into transaction nature and motivations.

What is IDXX's revenue and growth?

IDEXX LABORATORIES INC /DE reported revenue of $4.3B.

Does IDXX pay dividends?

IDEXX LABORATORIES INC /DE does not currently pay dividends.

Where can I find IDXX SEC filings?

Official SEC filings for IDEXX LABORATORIES INC /DE (CIK: 0000874716) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is IDXX's EPS?

IDEXX LABORATORIES INC /DE has a diluted EPS of $13.08.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.

Is IDXX a good stock to buy right now?

Based on our AI fundamental analysis in April 2026, IDEXX LABORATORIES INC /DE has a STRONG BUY rating with 88% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.

Is IDXX stock overvalued or undervalued?

Valuation metrics for IDXX: ROE of 66.0% (sector avg: 15%), net margin of 24.6% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.

Should I buy IDXX stock in 2026?

Our dual AI analysis gives IDEXX LABORATORIES INC /DE a combined STRONG BUY rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.

What is IDXX's free cash flow?

IDEXX LABORATORIES INC /DE's operating cash flow is $1.2B, with capital expenditures of $124.7M. FCF margin is 24.6%.

How does IDXX compare to other Default stocks?

Vs Default sector averages: Net margin 24.6% (avg: 12%), ROE 66.0% (avg: 15%), current ratio 1.23 (avg: 1.8).

Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Apr 11, 2026 | Data as of: 2025-12-31 | Powered by Claude AI